These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
168 related items for PubMed ID: 27929488
1. Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation. Salek N, Shamsaei M, Ghannadi Maragheh M, Shirvani Arani S, Bahrami Samani A. J Appl Clin Med Phys; 2016 Nov 08; 17(6):128-139. PubMed ID: 27929488 [Abstract] [Full Text] [Related]
2. Feasibility study for production and quality control of Yb-175 as a byproduct of no carrier added Lu-177 preparation for radiolabeling of DOTMP. Salek N, Shirvani Arani S, Bahrami Samani A, Vosoghi S, Mehrabi M. Australas Phys Eng Sci Med; 2018 Mar 08; 41(1):69-79. PubMed ID: 29260406 [Abstract] [Full Text] [Related]
3. Production, quality control, and determination of human absorbed dose of no carrier added 177 Lu-risedronate for bone pain palliation therapy. Salek N, Mehrabi M, Shirvani Arani S, Bahrami Samani A, Erfani M, Vosoghi S, Ghannadi Maragheh M, Shamsaei M. J Labelled Comp Radiopharm; 2017 Jan 08; 60(1):20-29. PubMed ID: 27862203 [Abstract] [Full Text] [Related]
4. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation. Abbasi IA. Nucl Med Biol; 2011 Apr 08; 38(3):417-25. PubMed ID: 21492790 [Abstract] [Full Text] [Related]
9. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Das T, Chakraborty S, Unni PR, Banerjee S, Samuel G, Sarma HD, Venkatesh M, Pillai MR. Appl Radiat Isot; 2002 Aug 08; 57(2):177-84. PubMed ID: 12150276 [Abstract] [Full Text] [Related]
11. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S. Appl Radiat Isot; 2008 Sep 08; 66(9):1196-205. PubMed ID: 18372188 [Abstract] [Full Text] [Related]
12. Radiolabeling, stability studies, and pharmacokinetic evaluation of thulium-170-labeled acyclic and cyclic polyaminopolyphosphonic acids. Vats K, Das T, Sarma HD, Banerjee S, Pillai MR. Cancer Biother Radiopharm; 2013 Dec 08; 28(10):737-45. PubMed ID: 23931111 [Abstract] [Full Text] [Related]
14. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent. Máthé D, Balogh L, Polyák A, Király R, Márián T, Pawlak D, Zaknun JJ, Pillai MR, Jánoki GA. Nucl Med Biol; 2010 Feb 08; 37(2):215-26. PubMed ID: 20152721 [Abstract] [Full Text] [Related]
15. Preparation and Dosimetry Evaluation of a Carrier- Free 90Y Labeled DOTMP as a Promising Agent for Bone Marrow Ablation. Salek N, Vosoghi S, Arani SS, Samani AB, Mehrabi M, Maraghe MG. Curr Radiopharm; 2018 Feb 08; 11(2):116-122. PubMed ID: 29651974 [Abstract] [Full Text] [Related]
16. Production, quality control, biodistribution assessment and preliminary dose evaluation of (177)Lu-PDTMP as a possible bone palliative agent. Yousefnia H, Jalilian AR, Zolghadri S, Ghannadi-Maragheh M. Nucl Med Commun; 2014 Jan 08; 35(1):99-107. PubMed ID: 24162837 [Abstract] [Full Text] [Related]